title: Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients.
abstract: To determine the single or combined effect of both rs12979860 and rs8099917 SNPs on HCV treatment response, these variants were genotyped in samples from a cohort of 170 patients infected with different HCV genotypes (HCVGT). The favourable rs12979860 CC genotype was found only in patients with sustained or rapid virological responses (SVR/RVR) and at significantly high proportions in HCVGT1/4 SVR patients. A significant association was also found between the rs8099917 TT genotype and SVR in both HCVGT1/4 and HCVGT2/3 groups of patients. In contrast, we found that there was significantly more of the rs8099917 GG genotype in nonresponders (NR) than in SVR patients which suggests a good association of the minor homozygote GG with the lack of treatment response. The combination of rs12979860/rs8099917 CC/TT favourable genotypes was found only in SVR patients and matched the frequency observed for their rs12979860 CC genotypes alone. By contrast, the inverse unfavourable correlate rs12979860/rs8099917 TT/GG genotype was seen more in NR than in SVR patients as observed for the single GG genotype. This study confirms the impact of both rs12979860 and/or rs8099917 IL-28B SNPs on treatment-induced clearance of HCV-RNA and demonstrates that the rs12979860 CC genotype is stronger than rs8099917 TT genotype in predicting a positive treatment response in HCVGT1/4 patients. The unfavourable rs8099917 GG genotype seems to be more important in predicting the failure of treatment response independently from HCV genotype.
authors.affiliation: Virology Section, Campus Bio-Medico University, Rome, Italy. e.riva@unicampus.it
authors.forename: E
authors.initials: E
authors.lastname: Riva
authors.forename: C
authors.initials: C
authors.lastname: Scagnolari
authors.forename: K
authors.initials: K
authors.lastname: Monteleone
authors.forename: C
authors.initials: C
authors.lastname: Selvaggi
authors.forename: A
authors.initials: A
authors.lastname: Picardi
authors.forename: C
authors.initials: C
authors.lastname: Mazzarelli
authors.forename: E
authors.initials: E
authors.lastname: Pizzigallo
authors.forename: B
authors.initials: B
authors.lastname: Vincenzi
authors.forename: A
authors.initials: A
authors.lastname: Carducci
authors.forename: S
authors.initials: S
authors.lastname: Antonaci
authors.forename: G
authors.initials: G
authors.lastname: Giannelli
authors.forename: G
authors.initials: G
authors.lastname: Antonelli
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics* / Q000276:immunology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D007378:Interleukins / Q000235:genetics* / Q000276:immunology; D007558:Italy; D008297:Male; D020641:Polymorphism, Single Nucleotide; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D007372:Interferons; D007378:Interleukins; D012254:Ribavirin; C000624353:interferon-lambda, human; D000095022:Interferon Lambda